Just how bad is it in the Alzheimer’s R&D arena?
IQVIA just put together something of an impressionist piece on the slew of trial failures recorded over the years (below).
Except for one pop in 2014 — for a dementia drug, Namzaric — there’s nothing by way of an FDA approval going back to 2002, 17 years of failure and disaster, with Eli Lilly, Pfizer, J&J and others going over the amyloid beta cliff.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,